US Broker Ratings

uniQure N.V. (QURE) Stock Analysis: Unveiling a 131% Potential Upside in the Biotech Sector

In the dynamic landscape of biotechnology, uniQure N.V. (NASDAQ: QURE) stands out with an impressive potential upside of 131.20%, making it an intriguing prospect for investors..

Immunome, Inc. (IMNM) Stock Analysis: Unveiling a 71.68% Upside Potential in the Fast-Paced Biotech Sector

Immunome, Inc. (NASDAQ: IMNM) is capturing the attention of investors with its promising position in the biotechnology industry. Specializing in the development of targeted cancer therapies,..

Maravai LifeSciences Holdings (MRVI) Stock Analysis: An 11.61% Upside in the Biotech Sector

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) has caught the attention of investors with its significant 11.61% potential upside, as reflected by the average analyst price target..

CeriBell, Inc. (CBLL) Stock Analysis: 31.82% Upside Potential and Strong Buy Ratings

CeriBell, Inc. (NASDAQ: CBLL), a medical technology company at the forefront of neurological patient care, is turning heads in the healthcare sector. With its innovative approach..

Spyre Therapeutics (SYRE) Stock Analysis: Uncovering a 62.49% Potential Upside in Biotechnology

Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company headquartered in Waltham, Massachusetts, has been capturing investor attention with its ambitious pipeline targeting inflammatory bowel disease..

AnaptysBio, Inc. (ANAB) Investor Outlook: Exploring a 36.95% Potential Upside in the Biotech Sector

AnaptysBio, Inc. (NASDAQ: ANAB), a clinical-stage biotechnology company based in San Diego, is making waves in the healthcare sector. With a robust focus on immunology therapeutics,..

Taysha Gene Therapies (TSHA) Stock Analysis: Biotech Innovator with 97.90% Upside Potential

Taysha Gene Therapies, Inc. (NASDAQ: TSHA) is positioned at the frontier of the biotechnology sector, offering investors a compelling opportunity in the realm of gene therapies..

Intellia Therapeutics, Inc. (NTLA) Stock Analysis: Exploring a 152.61% Potential Upside in Gene Editing Revolution

Intellia Therapeutics, Inc. (NASDAQ: NTLA) is making waves in the biotech sector with its groundbreaking focus on genome editing treatments, positioning itself as a critical player..

Neuropace, Inc. (NPCE) Stock Analysis: Unveiling a 22.3% Potential Upside in the Medical Device Sector

For investors seeking opportunities within the healthcare sector, particularly in the realm of medical devices, Neuropace, Inc. (NASDAQ: NPCE) presents an intriguing prospect. With a focus..

Evolus, Inc. (EOLS) Stock Analysis: Aiming High with Over 150% Potential Upside

Evolus, Inc. (NASDAQ: EOLS) is capturing the attention of investors with its significant growth potential, evidenced by a staggering 157.66% potential upside. As a key player..

Niagen Bioscience, Inc. (NAGE) Stock Analysis: A Biotech Gem with 143% Potential Upside

Niagen Bioscience, Inc. (NAGE), a prominent player in the biotechnology industry, has captured the attention of investors with its remarkable potential upside of 143.08%. Operating within..

Zymeworks Inc. (ZYME) Stock Analysis: A Promising Biotech Play with a 34.62% Upside Potential

For investors eager to capitalize on the burgeoning biotechnology sector, Zymeworks Inc. (NASDAQ: ZYME) presents an intriguing opportunity. With a market capitalization of $2 billion, this..

OrthoPediatrics Corp. (KIDS) Investor Outlook: Analysts Forecast 37% Upside Potential

OrthoPediatrics Corp. (NASDAQ: KIDS), a leader in the pediatric orthopedic medical devices sector, presents a compelling opportunity for investors seeking exposure to the healthcare industry. With..

Dianthus Therapeutics, Inc. (DNTH): Investor Outlook on a Biotech with 51% Upside Potential

Dianthus Therapeutics, Inc. (NASDAQ: DNTH), a pioneering entity in the biotechnology sector, has been capturing investor attention with its ambitious approach to treating severe autoimmune and..

CureVac N.V. (CVAC) Investor Outlook: Assessing a 26.20% Potential Upside in the Innovative mRNA Space

CureVac N.V. (NASDAQ: CVAC), a prominent player in the biotechnology sector, presents a compelling case for investors intrigued by the transformative potential of messenger RNA (mRNA)..

Akso Health Group (AHG) Stock Analysis: Unpacking the 415.8% Revenue Growth in China’s Booming Healthcare Sector

Akso Health Group (AHG), a prominent player in China’s medical distribution industry, is capturing headlines with its remarkable 415.8% revenue growth. As a healthcare company operating..

Syndax Pharmaceuticals, Inc. (SNDX) Stock Analysis: A 94.3% Upside Potential Amid Biotech Innovations

Individual investors eyeing the biotechnology sector may find Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) an intriguing prospect given its innovative cancer therapies and promising market performance indicators...

Delcath Systems, Inc. (DCTH) Investor Outlook: A 124% Potential Upside in the Expanding Oncology Market

Delcath Systems, Inc. (NASDAQ: DCTH) has recently captured the attention of investors with its notable potential upside of 124.62%, according to analyst ratings. As an interventional..

Enliven Therapeutics, Inc. (ELVN) Stock Analysis: Exploring a 148% Potential Upside

Enliven Therapeutics, Inc. (NASDAQ: ELVN), a clinical-stage biopharmaceutical company, is gaining attention in the biotechnology sector for its promising pipeline of cancer therapies. Headquartered in Boulder,..

Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Uncovering a 144.90% Potential Upside in the Biotech Arena

Gyre Therapeutics, Inc. (NASDAQ: GYRE), a promising player in the biotechnology sector, has caught the attention of individual investors with its substantial market cap of $708.05..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds